NCT00288444: Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer |
|
|
| Terminated | 1 | 38 | US | Lonafarnib, SCH66336, Docetaxel, Taxotere | Emory University, Aventis Pharmaceuticals, Schering-Plough | Lung Cancer, Soft Tissue Sarcoma, Colorectal Carcinoma, Breast Cancer, Prostate Cancer | 05/08 | 03/09 | | |
NCT00612651: PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas |
|
|
| Completed | 1 | 37 | US | Temodar and SCH 66336, Temodar-Temozolomide, Farnesyl transferase inhibitor-SCH 66336 | Duke University, Schering-Plough | Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma | 01/09 | 06/11 | | |
NCT00102648: Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide |
|
|
| Active, not recruiting | 1 | 35 | US | Lonafarnib, 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, Sarasar, SCH 66336, SCH-66336, SCH66336, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma | 12/22 | 12/22 | | |
